Using light to change glioma stem cells for better treatment outcomes
Patterned optogenetic neuromodulation to reprogram glioma stem cells
['FUNDING_R21'] · METHODIST HOSPITAL RESEARCH INSTITUTE · NIH-10816836
This study is exploring a new way to treat glioblastoma by using light to change the behavior of stubborn cancer cells, with the hope of making them easier to treat and improving outcomes for patients battling this tough brain cancer.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | METHODIST HOSPITAL RESEARCH INSTITUTE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10816836 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treating glioblastoma, a highly aggressive brain cancer, by targeting glioma stem-like cells (GSCs) that contribute to the cancer's resistance to standard therapies. The study employs patterned optogenetic neuromodulation to manipulate the electrical signals within these cells, aiming to reprogram them into a less malignant state that is more responsive to treatment. By altering the membrane potential of GSCs, the researchers hope to enhance the effectiveness of existing therapies like chemotherapy and radiation. This innovative method could lead to improved outcomes for patients suffering from this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded adequately to standard treatments.
Not a fit: Patients with glioblastoma who are in advanced stages of the disease or have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially extending survival and improving quality of life for patients.
How similar studies have performed: While the use of optogenetics in cancer treatment is a relatively novel approach, preliminary studies have shown promise in reprogramming cancer cells, suggesting potential for success in this area.
Where this research is happening
HOUSTON, UNITED STATES
- METHODIST HOSPITAL RESEARCH INSTITUTE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ROSTOMILY, ROBERT C — METHODIST HOSPITAL RESEARCH INSTITUTE
- Study coordinator: ROSTOMILY, ROBERT C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.